Dr. Amanda Lynn Gillespie-twardy M.D.

Recommended Articles

• AstraZeneca Gains United States Approval for Lymphoma Drug

  Some forms of lymphoma are rarer than others. Most people can recognize Hodgkin lymphoma, but mantle cell lymphoma will strike them as a surprise.Because it is so rare, there are not as many drugs specific to this form of cancer. One has recently been approved in the United States, by the Food and...

• How to Deal with Lymphoma Treatment Fatigue

  Treatment fatigue is a very common problem among lymphoma patients. Whether the patient is doing pharmaceutical treatments, chemotherapy, or other treatments, they will likely lead to fatigue and a feeling of being burnt out.This article will go over what treatment fatigue is, symptoms that are...

• The Promising Future of Gene Therapy and Lymphoma

  Non-Hodgkin lymphoma affects over 700,000 people in America alone. Though current treatments are moderately effective, especially for aggressive forms of the disease, more can be done to help people impacted by NHL. Researchers are doing just that by working to develop new, innovative treatment for...

• Promising Results for Hodgkin Patients Using This Therapy

  Researcher Dr. Bradford S. Hoppe and his colleagues at the University of Florida College of Medicine have recently found that the addition of proton therapy to first-line chemotherapy regimens may improve outcomes for patients with Hodgkin lymphoma.Lymphoma is classically treated with both...

• Genetic Advancements in Lymphoma Treatment

  Cancers are a huge focus for research. Millions of dollars every year are funneled into funding research that could improve treatment methods or find cures for cancer, including blood cancers. Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL) accounting...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...